Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11336151 | 0.88 | FAAH (0.46) | ALDH1A1TSHRKMT2AGAAMAPT | |
| SCHEMBL7973521 | 0.86 | FAAH (0.49) | ALDH1A1TSHRGAAMAPTSMN1; SMN2 | |
| SCHEMBL11244943 | 0.84 | FAAH (0.51) | ALDH1A1TSHRGAAMAPTSMN1; SMN2 | |
| SCHEMBL5443617 | 0.84 | FAAH (0.51) | ALDH1A1TSHRGAAMAPTSMN1; SMN2 | |
| SCHEMBL11523175 | 0.84 | FAAH (0.51) | ALDH1A1TSHRGAAMAPTSMN1; SMN2 | |
| SCHEMBL11596378 | 0.84 | FAAH (0.51) | ALDH1A1TSHRGAAMAPTSMN1; SMN2 | |
| SCHEMBL11596878 | 0.84 | FAAH (0.51) | ALDH1A1TSHRGAAMAPTSMN1; SMN2 | |
| SCHEMBL11594801 | 0.84 | FAAH (0.51) | ALDH1A1TSHRGAAMAPTSMN1; SMN2 | |
| SCHEMBL11595342 | 0.84 | FAAH (0.51) | ALDH1A1TSHRGAAMAPTSMN1; SMN2 | |
| SCHEMBL325076 | 0.83 | ALDH1A1 (0.62) | ALDH1A1TSHRKMT2AGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190169140-A1 | IDO1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | SHANDONG LUYE PHARMACEUTICAL CO., LTD. (CN) | 2019-06-06 | — | — | US | disclosed |
| US-7713859-B2 | Tin-silver solder bumping in electronics manufacture | ENTHONE INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20070037377-A1 | TIN-SILVER SOLDER BUMPING IN ELECTRONICS MANUFACTURE | ENTHONE INC. (US) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169140-A1 | IDO1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | IDO1, IDO2, INMT | ALDH1A1 304/4885TSHR 2879/4885KMT2A 1006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.